CVKD 17.42 Cadrenal Therapeutics, Inc. Common Stock
| Range: | 5.4-32.55 | Vol Avg: | 39187 | Last Div: | 0 | Changes: | 0.96 |
| Beta: | 0 | Cap: | 0.02B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri Jan 20 2023 | Empoloyees: | 4 | ||
| CUSIP: | CIK: | 0001937993 | ISIN: | US1276361086 | Country: | US | |
| CEO: | Mr. Quang X. Pham | Website: | https://www.cadrenal.com | ||||
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow